Improvement in treatment of hypertension has not reduced incidence of end-stage renal disease

Journal of Human Hypertension

Volumn 13, Issue 11, 1999, Pages 747-751

  Seedat, Y K ^a  

^a UNIVERSITY OF NATAL   (South Africa)

Author keywords

End stage renal disease; Hypertension; Treatment

Indexed keywords

ANTIHYPERTENSIVE AGENT;

AFRICA; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CONFERENCE PAPER; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY BLOOD FLOW; KIDNEY FAILURE; NEGRO; NEPHROSCLEROSIS; SOCIAL STATUS; STROKE; UNITED STATES;

EID: 0032740380     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000911     Document Type: Conference Paper

References (56)

1. US Renal Data System. USRDS 1992 Annual Data. Bethesda, MD. The National Institute of Diabetes and Digestive and Kidney Diseases, 1991.
2. SADTR Report 1994. Combined report on Maintenance Dialysis and Transplantation in the Republic of South Africa du Toit ED, Pascoe M, MacGregor K, Thomson PD (eds). 1994. Observatory, Cape Town, South Africa.
3. Blythe WB, Maddux FW. Hypertension as a causative diagnosis of patients entering end-stage renal disease programs in the United States from 1980 to 1986. Am J Kidney Dis 1991; 18: 33-37.
4. MacMahon SW, Cutler JA, Furberg CD, Payne GH. The effects of drug treatment for hypertension on morbidity and mortality and cardiovascular disease: a review of randomized controlled trials. Prog Cardiovasc Dis 1986; 29 (Suppl 1): 99-118.
5. Collins R, Peto R, MacMahon SW. Blood Pressure, stroke and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 765-774.
6. US Renal Data System. USRDS 1994 Annual Data Report. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Disease, 1994. (NIH publications No. 94-3176).
7. Seedat YK, Naiker S, Rawat R, Parsoo I. Racial differences in the causes of end-stage renal failure in Natal. S Afr Med J 1984; 65: 956-958.
8. Sommers SC, Melamed J. Renal pathology of essential hypertension. Am J Hypertens 1990; 3: 583-587.
9. Lafferty HM, Brenner BM. Are glomerular hypertension and 'hypertrophy' independent risk factors for progression of renal disease? Semin Nephrol 1990; 10: 294-304.
10. Aurell M. Aspects of the role of intraglomerular pressure as a cause of progressive renal damage. Drugs 1988; 35 (Suppl): 42-47.
11. Schlessinger SD, Tankersley MR, Curtis JJ. Clinical documentation of end-stage renal disease due to hypertension. Am J Kidney Dis 1994; 23: 655-660.
12. Brown MA, Whitworth JA. Hypertension in human renal disease. J Hypertens 1992; 10: 701-712.
13. Perneger TV, Whelton PK, Klag MJ, Rossiter KA. Diagnosis of hypertensive end-stage renal disease: effect of patient's race. Am J Epidemiol 1995; 141: 10-15.
14. Freedan BI, Iskandar SS, Appel RG. The link between hypertension and nephrosclerosis. Am J Kidney Dis 1995; 25: 207-221.
15. Subcommittee on Definition and Prevalence of the 1984 Joint National Committee. Hypertension prevalence and the status of awareness, treatment, and control in the United States. Hypertension 1985; 7: 457-468.
16. Rostand SG, Kirk KA, Rutsky EA, Pate BA. Racial differences in the incidence of treatment for end-stage renal disease. N Engl J Med 1982; 306: 1276-1279.
17. McClellan W, Tuttle E, Issa A. Racial differences in the incidence of hypertensive end-stage renal disease (ESRD) are not entirely explained by differences in the prevalence of hypertension. Am J Kidney Dis 1988; 12: 285-290.
18. Tierney WM, McDonald CJ, Luft FC. Renal disease in hypertensive adults: effect of race and type II diabetes mellitus. Am J Kidney Dis 1989; 13: 485-493.
19. Rostand SG et al. Renal insufficiency in treated essential hypertension. N Engl J Med 1989; 320: 684-688.
20. Perry HM et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995; 25 (Part 1): 587-594.
21. Walker G et al. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. JAMA 1992; 268: 3038-3091.
22. Whelton PK, Klag MJ. Hypertension as a risk factor for renal disease. Review of clinical and epidemiological evidence. Hypertension 1989; 13 (Suppl): I19-I27.
23. Rostand SG. Diabetic renal disease in blacks - inevitable or preventable? (Editorial). N Engl J Med 1989; 321: 1121-1122.
24. Young EW et al. Socio-economic status and end-stage renal disease in the United States. Kidney Int 1994; 45: 907-911.
25. Byrne C, Nedelman J, Luke RG. Race, socioeconomic status, and the development of end-stage renal disease. Am J Kidney Dis 1994; 23: 16-22.
26. Drizd T, Dannenberg AL, Engel A. Blood pressure levels in persons 18-74 years of age in 1976-80, and trends in blood pressure from 1960 to 1980 in the United States. In: Vital & Health Statistics: Data from The National Health Survey, 1986, (Series II, 234), pp 1-68.
27. Whittle JC, Whelton PK, Seidler AJ, Klag MJ. Does racial variation in risk factors explain black-white differences in the incidence of hypertensive end-stage renal disease? Arch Intern Med 1991; 151: 1359-1364.
28. Weinberger MH et al. Definitions and characteristics of sodium sensitivity and blood pressure resistance. Hypertension 1986; 8: II127-II134.
29. Campese VM, Parise M, Karubian F, Bigazzi R. Abnormal renal hemodynamics in black salt-sensitive patients with hypertension. Hypertension 1991; 18: 805-812.
30. Warren SE, O'Connor DT. Does a renal vasodilator system mediate racial differences in essential hypertension? Am J Med 1980; 69: 425-429.
31. O'Connor DT, Levine GL, Frigon RP. Homologous radio-immunoassay of human plasma dopamine-beta-hydroxylase: analysis of homospecific activity, circulating plasma pool and intergroup differences based on race, blood pressure and cardiac function. J Hypertens 1983; 1: 227-233.
32. Lilley JJ, Hsu L, Stone RA. Racial disparity of plasma volume in hypertensive man (letter). Ann Intern Med 1976; 84: 707-708.
33. Frohlich ED et al. Greater renal vascular involvement in the black patient with essential hypertension. A comparison of systemic and renal hemodynamics in black and white patients. Miner Elect Metab 1984; 10: 173-177.
34. Luft FC et al. Effects of Volume expansion and contraction in normotensive whites, blacks, and subjects of different ages. Circulation 1979; 59: 643-650.
35. Lopes AAS, Port FK. The low birth weight hypothesis as a plausible explanation for the black/white differences in hypertension, non-insulin-dependent diabetes, and end-stage renal disease. Am J Kidney Dis 1995; 25: 350-356.
36. Muirhead EE, Pitcock JA. Histopathology of severe vascular damage in blacks. Clin Cardiol 1989; 12: IV58-IV65.
37. Isaacson C, Milne FJ, van Niekerk I. Hypertension in black South Africans-new perspectives on old material. S Afr Med J 1989; 76: 323-324.
38. Madhavan S, Stockwell D, Cohen H, Alderman MH. Renal function during antihypertensive treatment. Lancet 1995; 345: 749-751.
39. Dustan HP. Does keloid pathogenesis hold the key to understanding black/white differences in hypertension severity? Hypertension 1995; 26 (Part 1): 858-862.
40. Burt VL et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995; 25: 305-313.
41. Rosansky SJ, Hoover DR, King L, Gibson J. The association of blood pressure levels and change in renal function in hypertensive and nonhypertensive subjects. Arch Intern Med 1990; 150: 2073-2076.
42. Klag MJ et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13-18.
43. Working Group on Risk and High Blood Pressure. An epidemiological approach to describing risk associated with blood pressure levels. Hypertension 1985; 7: 641-651.
44. Tolins JP, Shultz P, Raij L. Mechanisms of hypertensive glomerular injury. Am J Cardiol 1988; 62: 54G-58G.
45. Hollenberg NK, Raij L. Angiotensin-converting enzyme inhibition and renal protection. An assessment of implications for therapy. Arch Intern Med 1993; 153: 2426-2435.
46. Hollenberg NK, Fisher ND. Renal circulation and blockade of the renin-angiotensin system. Is angiotensin-converting enzyme inhibition the last word? Hypertension 1995; 26: 602-609.
47. Pettinger WA, Lee HC, Reisch J, Mitchell HC. Long-term improvement in renal function after short-term strict blood pressure control in hypertensive nephrosclerosis. Hypertension 1989; 13: 766-772.
48. Hannedouche T et al. Randomized controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ 1994; 309: 833-837.
49. Bianchi S et al. Long-term effects of enalapril and nicardipine on urinary albumin excretion in patients with chronic renal insufficiency: a 1 year follow-up. Am J Nephrol 1991; 11: 131-137.
50. Maschio G et al. Effect of angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334: 939-945.
51. Zuchelli P, Zuccala A, Gaggi R. Calcium channel blockers: effects on progressive renal disease. Am J Kidney Dis 1991; 17 (Suppl 1): 94-97.
52. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs hyperplasia: autocrine transforming growth factor - δ expression determines growth response to angiotensin II. J Clin Invest 1992; 90: 456-461.
53. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994; 93: 2431-2437.
54. Egido J. Vasoactive hormones and renal sclerosis. Kidney Int 1996; 49: 578-597.
55. Kazda S. Future prospects for calcium antagonists. Drugs 1994; 48: (Suppl 1): 32-39.
56. Brown DM et al. Renal disease susceptibility and hypertension are under independent genetic control in the fawn-hooded rat. Nat Genet 1996; 12: 44-51.